VF
SGMT icon

Virtu Financial’s Sagimet Biosciences SGMT Stock Holding History

Virtu Financial’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,438
Closed -$62K – 2238
2025
Q4 		$62K Buy
+10,438
New +$75K ﹤0.01% 1278
2025
Q3 		– Sell
-27,740
Closed -$211K – 2024
2025
Q2 		$211K Buy
+27,740
New +$117K 0.01% 897
2025
Q1 		– Sell
-25,043
Closed -$113K – 1966
2024
Q4 		$113K Sell
25,043
-9,123
-27% -$46.2K 0.01% 997
2024
Q3 		$95K Sell
34,166
-17,677
-34% -$54.5K 0.01% 924
2024
Q2 		$177K Buy
+51,843
New +$238K 0.01% 744
2024
Q1 		– Sell
-12,301
Closed -$67K – 2024
2023
Q4 		$67K Buy
+12,301
New +$58K 0.01% 1125

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Virtu Financial's SGMT Position: Q1 2026 in Review

Virtu Financial sold out of Sagimet Biosciences (SGMT) in Q1 2026, closing a stake of 10,438 shares — an estimated $62K sold.

Virtu Financial first reported a position in SGMT in Q4 2023 and held it in 6 quarters. The position peaked at $211K in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Virtu Financial reported no remaining Sagimet Biosciences position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 10,438 Sagimet Biosciences shares in Q1 2026, an estimated $62K.
  • Virtu Financial first reported a position in Sagimet Biosciences in Q4 2023 and held it in 6 quarters.
  • Virtu Financial's Sagimet Biosciences position peaked at $211K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.